rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Susan E. Graf

Director

Company insider

Files Form 4 as: Director, Aardvark Therapeutics; Director, CG Oncology; Director, Finch Therapeutics Group; Chief Business Officer, Epizyme; VP,Corp Development & Strategy, Nps Pharmaceuticals.

Every Form 4 they filed

In numbers

Trades disclosed
34
Buys
1
Sells
1
Bought
$1,353
Sold
$308K
Companies
5
Companies where not an officer
3
First trade
17 Jun 2013
Last trade
14 Aug 2026
Last filed
21 Aug 2026

Companies traded

Where they are an officer
EpizymeOfficer · last 9 Feb 20180 buys · 0 sells
Nps PharmaceuticalsOfficer · last 21 Feb 20150 buys · 1 sell
Everywhere else they filed: board seats, 10% stakes, other companies
AARD Aardvark TherapeuticsDirector · Biotechnology · last 14 Aug 20260 buys · 0 sells
CGON CG OncologyDirector · Biotechnology · last 4 Jun 20260 buys · 0 sells
Finch Therapeutics GroupDirector · last 9 Jun 20231 buy · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
14 Aug 2026filed 21 Aug 2026AARD Aardvark Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—44,964 at $0.00filing
14 Aug 2026filed 21 Aug 2026AARD Aardvark Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—44,964 at $0.00filing
4 Jun 2026filed 5 Jun 2026CGON CG Oncologyoption or derivative · BiotechnologySEC FORM 4 Code A—9,354 at $0.00filing
4 Jun 2026filed 5 Jun 2026CGON CG Oncologyoption or derivative · BiotechnologySEC FORM 4 Code A—9,354 at $0.00filing
11 Jun 2025filed 13 Jun 2025AARD Aardvark Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—30,508 at $0.00filing
5 Jun 2025filed 6 Jun 2025CGON CG Oncologyoption or derivative · BiotechnologySEC FORM 4 Code A—24,165 at $0.00filing
4 Oct 2024filed 7 Oct 2024CGON CG Oncologyoption or derivative · BiotechnologySEC FORM 4 Code A—15,600 at $0.00filing
9 Jun 2023filed 9 Jun 2023Finch Therapeutics GroupSEC FORM 4 Bought$1,3535,010 at $0.27filing
8 Jun 2023filed 9 Jun 2023Finch Therapeutics Groupoption or derivativeSEC FORM 4 Code A—10,000 at $0.00filing
13 Jun 2022filed 15 Jun 2022Finch Therapeutics Groupoption or derivativeSEC FORM 4 Code A—44,843 at $0.00filing
23 Apr 2021filed 27 Apr 2021Finch Therapeutics Groupoption or derivativeSEC FORM 4 Code A—23,419 at $0.00filing
9 Feb 2018filed 13 Feb 2018Epizymeoption or derivativeSEC FORM 4 Code A—106,344 at $0.00filing
8 Feb 2017filed 9 Feb 2017Epizymeoption or derivativeSEC FORM 4 Code A—109,866 at $0.00filing
25 Apr 2016filed 26 Apr 2016Epizymeoption or derivativeSEC FORM 4 Code A—178,642 at $0.00filing
21 Feb 2015filed 24 Feb 2015Nps PharmaceuticalsSEC FORM 4 Code U$219K4,761 at $46.00filing
21 Feb 2015filed 24 Feb 2015Nps Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—41,289filing
21 Feb 2015filed 24 Feb 2015Nps Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—11,874filing
21 Feb 2015filed 24 Feb 2015Nps Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—10,905filing
21 Feb 2015filed 24 Feb 2015Nps Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—2,893filing
21 Feb 2015filed 24 Feb 2015Nps Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—11,577filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Not placed2

Buys in green, sells in red, by the company’s sector.

Related people

Nobody else traded the same names lately.